LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lexeo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.76+0.12 (+4.55%)
Close on Oct 19, 2026
- Market cap
- $236.33M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
90M of 82M shares
Institutional holders
142
28 new, 22 sold out
Net institutional buying
15M
In Q2 2026
Insider trades, 12 months
0 buys · 17 sales
Net sold $751.98K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bam Gp LLC | 7,844,311 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Janus Henderson Group PLC | 7,291,434 | 9.99% | 13G (passive) amendment | Nov 28, 2025 |
| Dames GP LLC | 7,221,555 | 9.89% | 13G (passive) amendment | Dec 31, 2025 |
| Balyasny Asset Management Holdings LP | 7,176,144 | 9.69% | 13G (passive) amendment | Mar 31, 2026 |
| Affinity Asset Advisors, LLC | 6,674,913 | 8.40% | 13G (passive) amendment | Jun 30, 2026 |
| Paradigm BioCapital Advisors GP LLC | 6,184,134 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
| Aaron Cowen | 5,674,778 | 7.70% | 13G (passive) | Apr 6, 2026 |
| James N. Topper | 5,500,812 | 9.90% | 13G (passive) | May 28, 2025 |
| Kenneth Griffin | 5,498,219 | 7.40% | 13G (passive) amendment | Dec 31, 2025 |
| Dmitry Balyasny | 5,394,721 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Michael Cho | 5,217,660 | 7.10% | 13G (passive) amendment | Jan 22, 2026 |
| Peter Kolchinsky | 5,000,000 | 6.90% | 13G (passive) | Oct 20, 2025 |
| BlackRock, Inc. | 4,885,814 | 6.70% | 13G (passive) | Dec 31, 2025 |
| Paradigm BioCapital Advisors LP | 4,763,198 | 6.50% | 13G (passive) amendment | Dec 31, 2025 |
| JPMorgan Chase & Co. | 4,573,701 | 5.50% | 13G (passive) | Sep 30, 2026 |
| State Street Corporation | 4,354,775 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Affinity Healthcare Fund, LP | 4,252,005 | 7.75% | 13G (passive) | May 28, 2025 |
| Senai Asefaw, M.D. | 4,175,382 | 5.30% | 13G (passive) amendment | Jun 30, 2026 |
| Vestal Point Capital, LP | 4,117,302 | 7.50% | 13G (passive) amendment | Sep 30, 2025 |
| Fhmlsp, L.P. | 3,698,271 | 5.10% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LXEO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 6,384,200 | 7.78% | $29.72M | +5,134,200 | 0.54% |
| Affinity Asset Advisors, LLC | 5,807,611 | 7.08% | $27.03M | +757,400 | 1.22% |
| BlackRock, Inc. | 5,739,455 | 7.00% | $26.72M | +628,584 | 0.00% |
| Ra Capital Management, L.P. | 5,000,000 | 6.09% | $23.28M | – | 0.20% |
| Frazier Life Sciences Management, L.P. | 4,824,725 | 5.88% | $22.46M | +400,000 | 0.49% |
| State Street Corp | 4,354,757 | 5.31% | $20.27M | +786,515 | 0.00% |
| Vestal Point Capital, LP | 4,320,000 | 5.27% | $20.11M | −155,000 | 0.47% |
| Paradigm Biocapital Advisors LP | 4,175,382 | 5.09% | $19.44M | −2,008,752 | 0.36% |
| Jupiter Topco LLC | 3,954,691 | 4.82% | $18.41M | New | 0.01% |
| Orbimed Advisors LLC | 3,947,850 | 4.81% | $18.38M | +345,400 | 0.34% |
| Citadel Advisors LLC | 3,898,570 | 4.75% | $18.15M | +63,571 | 0.00% |
| Vanguard Capital Management LLC | 3,125,893 | 3.81% | $14.55M | +118,800 | 0.00% |
| Millennium Management LLC | 2,833,622 | 3.45% | $13.19M | +1,220,842 | 0.00% |
| Nantahala Capital Management, LLC | 2,600,000 | 3.17% | $12.10M | +1,400,000 | 0.20% |
| Woodline Partners LP | 2,500,532 | 3.05% | $11.64M | −250,000 | 0.04% |
| Balyasny Asset Management L.P. | 2,412,742 | 2.94% | $11.23M | +823,157 | 0.01% |
| Goldman Sachs Group Inc | 2,149,612 | 2.62% | $10.01M | +199,727 | 0.00% |
| 683 Capital Management, LLC | 1,875,000 | 2.29% | $8.73M | +675,000 | 0.43% |
| Geode Capital Management, LLC | 1,747,959 | 2.13% | $8.14M | +234,182 | 0.00% |
| ADAR1 Capital Management, LLC | 1,565,950 | 1.91% | $7.29M | +98,600 | 0.33% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 142 | 90M | 100.0% | 28 / 59 | 39 / 22 | 21M | 7M |
| Q1 2026 | 139 | 80M | 97.4% | 21 / 58 | 38 / 27 | 15M | 8M |
| Q4 2025 | 146 | 76M | 93.2% | 47 / 61 | 26 / 9 | 34M | 7M |
| Q3 2025 | 109 | 49M | 60.1% | 26 / 50 | 15 / 7 | 10M | 3M |
| Q2 2025 | 90 | 42M | 51.5% | 17 / 36 | 17 / 15 | 19M | 5M |
| Q1 2025 | 88 | 28M | 34.1% | 17 / 25 | 23 / 18 | 4M | 6M |
| Q4 2024 | 90 | 30M | 36.0% | 29 / 29 | 12 / 8 | 4M | 4M |
| Q3 2024 | 69 | 30M | 36.4% | 16 / 36 | 9 / 6 | 8M | 4M |
| Q2 2024 | 60 | 27M | 32.4% | 15 / 27 | 13 / 9 | 5M | 1M |
| Q1 2024 | 54 | 23M | 28.2% | 28 / 18 | 5 / 5 | 7M | 0M |
| Q4 2023 | 31 | 16M | 19.7% | 31 / 0 | 0 / 0 | 16M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LXEO | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,429,592 | 2.96% | $11.31M | 0.11% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,335,144 | 2.85% | $10.87M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,846,016 | 2.25% | $8.59M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 776,529 | 0.95% | $3.21M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 715,413 | 0.87% | $3.33M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 665,326 | 0.81% | $3.10M | 0.02% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 566,200 | 0.69% | $2.64M | 0.09% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 561,264 | 0.68% | $2.61M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 435,053 | 0.53% | $2.03M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 339,114 | 0.41% | $1.74M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 308,002 | 0.38% | $1.58M | 0.00% | May 31, 2026 |
| Small Cap Value Fund | 261,109 | 0.32% | $1.22M | 0.18% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 254,051 | 0.31% | $1.05M | 0.01% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 238,249 | 0.29% | $1.11M | 0.07% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 232,132 | 0.28% | $958.71K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard Nolan Townsend | Chief Executive Officer, Director | 376,778 | 0.46% | Sep 28, 2026 |
| Narinder Pal Bhalla | Chief Medical Officer | 84,908 | 0.10% | Sep 28, 2026 |
| Jose Manuel Otero | Chief Operating Officer | 138,288 | 0.17% | Sep 28, 2026 |
| Louis Edward Tamayo | Chief Financial Officer | 92,907 | 0.11% | Sep 28, 2026 |
| Jenny Robertson | Chief Legal Officer | 68,381 | 0.08% | Nov 20, 2025 |
| Tai Sandi See | Chief Development Officer | 65,476 | 0.08% | Nov 20, 2025 |
| Eric Adler | Chief Medical Officer | 72,646 | 0.09% | Nov 20, 2025 |
| Kyle Rasbach | Chief Financial Officer | 40,875 | 0.05% | Jan 22, 2025 |
| Paula H. Cholmondeley | Director | 30,627 | 0.04% | Jun 29, 2026 |
| Brenda Cooperstone | Director | – | – | Jun 29, 2026 |
| Mette Kirstine Agger | Director | – | – | Jun 29, 2026 |
| Tolga Tanguler | Director | – | – | Jun 29, 2026 |
| Reinaldo M. Diaz | Director | – | – | Jun 29, 2026 |
| Steven Altschuler | Director | – | – | Jun 29, 2026 |
| Hauwermeiren Timothy Van | Director | – | – | Jun 29, 2026 |
| Laura Sepp-Lorenzino | Director | – | – | Apr 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jose Manuel Otero Chief Operating Officer | Sep 14, 2026 | Award | +2,110 | $2.64 | $5.57K | 138,288 |
| Narinder Pal Bhalla Chief Medical Officer | Sep 14, 2026 | Award | +2,714 | $3.58 | $9.72K | 84,908 |
| Richard Nolan Townsend Chief Executive Officer, Director | Sep 14, 2026 | Award | +2,306 | $2.64 | $6.09K | 376,778 |
| Louis Edward Tamayo Chief Financial Officer | Aug 18, 2026 | Sale | −4,117 | $4.91 | $20.21K | 92,907 |
| Jose Manuel Otero Chief Operating Officer | Aug 18, 2026 | Sale | −1,304 | $4.96 | $6.47K | 136,178 |
| Richard Nolan Townsend Chief Executive Officer, Director | Aug 18, 2026 | Sale | −3,345 | $4.95 | $16.56K | 374,472 |
| Richard Nolan Townsend Chief Executive Officer, Director | Jul 1, 2026 | Sale | −25,947 | $4.48 | $116.24K | 377,817 |
| Louis Edward Tamayo Chief Financial Officer | Jul 1, 2026 | Sale | −4,641 | $4.49 | $20.84K | 97,024 |
| Narinder Pal Bhalla Chief Medical Officer | Jul 1, 2026 | Sale | −22,306 | $4.42 | $98.59K | 82,194 |
| Jose Manuel Otero Chief Operating Officer | Jul 1, 2026 | Sale | −4,666 | $4.48 | $20.90K | 137,482 |
| Richard Nolan Townsend Chief Executive Officer, Director | Jun 29, 2026 | Award | +67,000 | – | – | 403,764 |
| Louis Edward Tamayo Chief Financial Officer | Jun 29, 2026 | Award | +12,000 | – | – | 101,665 |
| Narinder Pal Bhalla Chief Medical Officer | Jun 29, 2026 | Award | +55,000 | – | – | 104,500 |
| Jose Manuel Otero Chief Operating Officer | Jun 29, 2026 | Award | +12,060 | – | – | 142,148 |
| Richard Nolan Townsend Chief Executive Officer, Director | May 18, 2026 | Sale | −3,342 | $5.06 | $16.91K | 336,764 |
| Jose Manuel Otero Chief Operating Officer | May 18, 2026 | Sale | −1,302 | $5.07 | $6.60K | 130,088 |
| Richard Nolan Townsend Chief Executive Officer, Director | Apr 6, 2026 | Sale(10b5-1 plan) | −55,000 | $5.69 | $312.95K | 340,106 |
| Richard Nolan Townsend Chief Executive Officer, Director | Mar 13, 2026 | Award | +2,623 | $2.64 | $6.92K | 395,106 |
| Jose Manuel Otero Chief Operating Officer | Mar 13, 2026 | Award | +5,930 | $2.64 | $15.66K | 131,390 |
| Jose Manuel Otero Chief Operating Officer | Feb 18, 2026 | Sale | −3,016 | $6.40 | $19.30K | 125,460 |
| Richard Nolan Townsend Chief Executive Officer, Director | Feb 18, 2026 | Sale | −10,173 | $6.38 | $64.90K | 392,483 |
| Narinder Pal Bhalla Chief Medical Officer | Feb 13, 2026 | Award | +49,500 | – | – | 49,500 |
| Louis Edward Tamayo Chief Financial Officer | Feb 4, 2026 | Award | +44,665 | – | – | 89,665 |
| Richard Nolan Townsend Chief Executive Officer, Director | Feb 4, 2026 | Award | +161,665 | – | – | 402,656 |
| Jose Manuel Otero Chief Operating Officer | Feb 4, 2026 | Award | +65,000 | – | – | 128,476 |
| Jose Manuel Otero Chief Operating Officer | Nov 18, 2025 | Sale | −721 | $9.27 | $6.68K | 63,476 |
| Tai Sandi See Chief Development Officer | Nov 18, 2025 | Sale | −386 | $9.27 | $3.58K | 65,476 |
| Eric Adler Chief Medical Officer | Nov 18, 2025 | Sale | −615 | $9.27 | $5.70K | 72,646 |
| Richard Nolan Townsend Chief Executive Officer, Director | Nov 18, 2025 | Sale | −1,127 | $9.27 | $10.45K | 240,991 |
| Jenny Robertson Chief Legal Officer | Nov 18, 2025 | Sale | −549 | $9.27 | $5.09K | 68,381 |
| Eric Adler Chief Medical Officer | Oct 17, 2025 | Sale | −3,344 | $8.94 | $29.90K | 73,299 |
| Eric Adler Chief Medical Officer | Oct 17, 2025 | Sale | −38 | $9.56 | $363 | 73,261 |
| Tai Sandi See Chief Development Officer | Oct 17, 2025 | Sale | −3,844 | $8.94 | $34.37K | 65,906 |
| Tai Sandi See Chief Development Officer | Oct 17, 2025 | Sale | −44 | $9.56 | $421 | 65,862 |
| Jose Manuel Otero Chief Technical Officer | Oct 17, 2025 | Sale | −24 | $9.56 | $229 | 64,197 |
| Jose Manuel Otero Chief Technical Officer | Oct 17, 2025 | Sale | −2,091 | $8.94 | $18.69K | 64,221 |
| Richard Nolan Townsend Chief Executive Officer, Director | Oct 17, 2025 | Sale | −148 | $9.56 | $1.41K | 242,118 |
| Richard Nolan Townsend Chief Executive Officer, Director | Oct 17, 2025 | Sale | −12,985 | $8.94 | $116.09K | 242,266 |
| Jenny Robertson Chief Legal Officer | Oct 17, 2025 | Sale | −3,486 | $8.94 | $31.16K | 68,970 |
| Jenny Robertson Chief Legal Officer | Oct 17, 2025 | Sale | −40 | $9.56 | $382 | 68,930 |
| Eric Adler Chief Medical Officer | Oct 15, 2025 | Award | +9,570 | – | – | 76,643 |
| Tai Sandi See Chief Development Officer | Oct 15, 2025 | Award | +10,890 | – | – | 69,750 |
| Jose Manuel Otero Chief Technical Officer | Oct 15, 2025 | Award | +5,940 | – | – | 66,312 |
| Richard Nolan Townsend Chief Executive Officer, Director | Oct 15, 2025 | Award | +33,000 | – | – | 255,251 |
| Jenny Robertson Chief Legal Officer | Oct 15, 2025 | Award | +9,900 | – | – | 72,456 |
| Richard Nolan Townsend Chief Executive Officer, Director | Sep 12, 2025 | Award | +2,193 | $2.64 | $5.79K | 222,251 |
| Louis Edward Tamayo Chief Financial Officer | Aug 29, 2025 | Award | +45,000 | – | – | 45,000 |
| Jose Manuel Otero Chief Technical Officer | Aug 18, 2025 | Sale | −721 | $9.27 | $6.68K | 63,476 |
| Richard Nolan Townsend Chief Executive Officer, Director | Aug 18, 2025 | Sale | −1,115 | $4.67 | $5.21K | 220,058 |
| Tai Sandi See Chief Development Officer | Aug 18, 2025 | Sale | −382 | $4.67 | $1.78K | 58,860 |
| Richard Nolan Townsend Chief Executive Officer, Director | Aug 18, 2025 | Sale | −2,735 | $4.67 | $12.77K | 220,058 |
| Jose Manuel Otero Chief Technical Officer | Aug 18, 2025 | Sale | −2,848 | $4.67 | $13.30K | 60,372 |
| Jenny Robertson Chief Legal Officer | Aug 18, 2025 | Sale | −542 | $4.67 | $2.53K | 62,556 |
| Eric Adler Chief Medical Officer | Aug 18, 2025 | Sale | −608 | $4.67 | $2.84K | 67,073 |
| Eric Adler Chief Medical Officer | May 16, 2025 | Sale | −585 | $2.77 | $1.62K | 67,681 |
| Jenny Robertson Chief Legal Officer | May 16, 2025 | Sale | −521 | $2.77 | $1.44K | 63,098 |
| Richard Nolan Townsend Chief Executive Officer, Director | May 16, 2025 | Sale | −1,074 | $2.77 | $2.97K | 221,173 |
| Tai Sandi See Chief Development Officer | May 16, 2025 | Sale | −367 | $2.77 | $1.02K | 59,242 |
| Jose Manuel Otero Chief Technical Officer | Mar 14, 2025 | Award | +5,720 | $2.61 | $14.93K | 63,220 |
| Jenny Robertson Chief Legal Officer | Mar 14, 2025 | Award | +5,720 | $2.61 | $14.93K | 63,619 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard Nolan Townsend Officer, Director | Aug 18, 2026 | 3,345 | $16.56K | Aug 18, 2026 | Restricted Stock Vesting |
| Jose Manuel Otero Officer | Aug 18, 2026 | 1,304 | $6.46K | Aug 18, 2026 | Restricted Stock Vesting |
| Louis Edward Tamayo Officer | Aug 18, 2026 | 4,117 | $20.20K | Aug 18, 2026 | Restricted Stock Vesting |
| Richard Nolan Townsend Officer, Director | Jul 1, 2026 | 25,947 | $116.19K | Jul 1, 2026 | Restricted Stock Vesting |
| Narinder Pal Bhalla Officer | Jul 1, 2026 | 22,306 | $98.68K | Jul 1, 2026 | Restricted Stock Vesting |
| Louis Edward Tamayo Officer | Jul 1, 2026 | 4,641 | $20.81K | Jul 1, 2026 | Restricted Stock Vesting |
| Jose Manuel Otero Officer | Jul 1, 2026 | 4,666 | $20.92K | Jul 1, 2026 | Restricted Stock Vesting |
| Richard Nolan Townsend Officer, Director | May 18, 2026 | 3,342 | $16.93K | May 18, 2026 | Restricted Stock Vesting |
| Jose Manuel Otero Officer | May 18, 2026 | 1,302 | $6.61K | May 18, 2026 | Restricted Stock Vesting |
| Eric Adler Officer | May 18, 2026 | 1,595 | $8.07K | May 18, 2026 | Restricted Stock Vesting |
| Nolan Townsend Richard Director, Officer | Apr 6, 2026 | 55,000 | $314.60K | Apr 6, 2026 | CS-3 Incentive Units |
| Tai Sandi See Officer | Feb 18, 2026 | 3,861 | $24.68K | Feb 18, 2026 | Restricted Stock Vesting |
| Richard Nolan Townsend Officer, Director | Feb 18, 2026 | 11,374 | $72.59K | Feb 18, 2026 | Restricted Stock Vesting |
| Eric Adler Officer | Feb 18, 2026 | 4,867 | $31.14K | Feb 18, 2026 | Restricted Stock Vesting |
| Jenny Robertson Officer | Feb 18, 2026 | 3,736 | $23.90K | Feb 18, 2026 | Restricted Stock Vesting |